Table 1.
Discovery cohort: baseline characteristics of patients (n = 778)
| Characteristics | Cases (N = 275) | Hypercontrols (N = 503) | p |
|---|---|---|---|
| Recipient age: mean ± SD (years) | 48.3 ± 14.1 | 48.6 ± 13.4 | 0.77 |
| Recipient sex (male): n (%) | 179 (65.1) | 331 (65.8) | 0.84 |
| Type of donor (deceased): n (%) | 263 (95.6) | 481 (95.8) | 0.91 |
| Donor age: mean ± SD (years) | 47.2 ± 15.9 | 44.7 ± 15.9 | 0.035 |
| Donor sex (male): n (%) | 148 (54) | 294 (60) | 0.11 |
| Cold ischemia time: mean ± SD (h) | 19.4 ± 7.7 | 18.3 ± 7.9 | 0.07 |
| Dialysis duration: median (P25–P75) (m) | 18 (8.9–36) | 18 (9.5–30.8) | 0.97 |
| Primary nephropathy: n | |||
| Glomerulopathy | 80 | 143 | 0.45 |
| Nephroangiosclerosis/hypertension | 25 | 24 | |
| Polycystic kidney disease | 52 | 107 | |
| Diabetic | 13 | 22 | |
| Chronic interstitial nephropathy | 30 | 54 | |
| Uncertain | 33 | 73 | |
| Other | 18 | 35 | |
| Congenital/hereditary | 22 | 44 | |
| Steroids at 6 months (yes): n (%) | 249 (93.3) | 328 (65.7) | <0.0001 |
| Tacrolimus/cyclosporin: n | 92/183 | 204/299 | 0.05 |
| Induction (thymoglobulin/IL2R antagonist): n | 75/200 | 154/349 | 0.33 |
| HLA‐A MM (0/1/2): n | 38/149/86 | 47/270/186 | 0.09 |
| HLA‐B MM (0/1/2): n | 25/129/119 | 21/215/267 | 0.003 |
| HLA‐DR MM (0/1/2): n | 30/154/88 | 10/272/221 | 0.0003 |
| HLA B+DR MM: mean ± SD | 2.56 ± 0.93 | 2.91 ± 0.71 | <0.0001 |
| HLA A+B+DR MM: mean ± SD | 3.73 ± 1.24 | 4.20 ± 0.95 | <0.0001 |
MM, mismatch; SD, standard deviation.